The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
暂无分享,去创建一个
T. Shen | G. Siegal | Gene P Siegal | Tiansheng Shen | Shi Wei | Shi Wei | Kai Wang | Kai Wang
[1] Molin Wang,et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F M Blows,et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] G. Tse,et al. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers , 2013, Breast Cancer Research and Treatment.
[4] A. Campbell,et al. Flow cytometric analysis of tumour-draining lymph nodes in breast cancer patients. , 1992, European journal of cancer.
[5] A. Rubbert,et al. Functional characterization of tumor‐infiltrating lymphocytes, lymph‐node lymphocytes and peripheral‐blood lymphocytes from patients with breast cancer , 1991, International journal of cancer.
[6] M. Piccart,et al. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial , 2017, Journal of the National Cancer Institute.
[7] E. Gonzalez-Billalabeitia,et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer , 2014, Breast Cancer Research.
[8] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Yamaguchi,et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. , 2012, Human pathology.
[10] P. Tan,et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer , 2016, Breast Cancer Research and Treatment.
[11] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. , 2011, Current oncology.
[13] A. Ribeiro-Silva,et al. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. , 2006, Clinics.
[14] W. Foulkes,et al. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade , 2011, Histopathology.
[15] Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Zhou,et al. Intratumoral CD8+ Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer , 2014, PloS one.
[17] S. Leung,et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer , 2012, Breast Cancer Research.
[18] C. Gerlinger,et al. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression , 2014, Archives of Gynecology and Obstetrics.
[19] Harry Bartelink,et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.
[20] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[21] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Gelber,et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 , 2016, Breast Cancer Research and Treatment.
[23] Ian O Ellis,et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] K. Knutson,et al. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[25] Carsten Denkert,et al. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.
[26] S. Rosenberg,et al. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion , 2005, Cancer Immunology, Immunotherapy.
[27] S. Pyrhönen,et al. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma , 2004, Melanoma research.
[28] A. Fattorossi,et al. Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T‐cell receptor Vβ repertoire , 2003, Immunology.
[29] Z. Ren,et al. Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.
[30] Yul Ri Chung,et al. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status , 2017, Breast Cancer Research and Treatment.
[31] Hongwei Chen,et al. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix , 2010, Cellular and Molecular Immunology.
[32] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] R. Matkowski,et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. , 2009, Anticancer research.
[34] Kathleen A Cronin,et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.
[35] C. Sotiriou,et al. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer , 2017, Journal of the National Cancer Institute.
[36] R. Sakalauskas,et al. The prognostic influence of tumor infiltrating Foxp3+CD4+, CD4+ and CD8+ T cells in resected non-small cell lung cancer , 2015, Journal of Inflammation.
[37] B. Sheu,et al. Reversed CD4/CD8 ratios of tumor‐infiltrating lymphocytes are correlated with the progression of human cervical carcinoma , 1999, Cancer.
[38] C. Croce,et al. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. , 2014, Journal of the National Cancer Institute.
[39] S. Vowler,et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. , 2006, Journal of hepatology.
[40] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[41] D. Yin,et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.
[42] Jae Hyun Kim,et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer , 2013, British Journal of Cancer.